OrthoPediatrics Q4 revenue up 25% to $31M; guides FY2023 revenue $146-149M

ORTHOPEDIATRICS CORP

2022-FY EPS reported $0.06 revenue$122,289,000

Q4 2022 revenue $31.0M (+25% YoY); FY2022 revenue $122.3M (+25% vs 2021).
GAAP net loss in Q4 $7.8M ($0.35/share) vs net income $0.1M in Q4 2021; FY2022 net income $1.3M ($0.06/share).
Adjusted EBITDA loss $2.2M in Q4 vs loss $0.6M a year ago; FY2022 adjusted EBITDA positive $0.2M.
Trauma & Deformity segment Q4 revenue $22.1M (+34% YoY); Scoliosis $8.0M (+12%); Sports Med/Other $0.9M (-22%).
International revenue grew 67% in Q4 and 47% for FY2022; cash $119.8M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ORTHOPEDIATRICS CORP reported the fourth quarter and full year ended December 31, 2022 results: revenue $31.0 million. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $31.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

bringing the total to more than 630,000 since the inception of OrthoPediatrics when combined with MD Orthopaedics ("MD Ortho") and Pega Medical • Generated total revenue of $31.0 million for fourth quarter 2022, up 25% from $24.8 million in fourth quarter 2021; domestic revenue increased 15% and international revenue increased 67% in 2022 • Generated record total

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.